HOME >> BIOLOGY >> NEWS
Down Syndrome protein reduces tumor growth

Bethesda, MD Scientists have found that overexpression of a protein called Down Syndrome Critical Region 1 (DSCR-1) blocks the formation of new blood vessels and thus reduces tumor growth. Therapeutics based on this finding may potentially lead to new cancer treatments.

The research appears as the "Paper of the Week" in the November 26 issue of the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal.

Many vascular disorders including atherosclerosis, tumor growth, and inflammation are caused by the activation and dysfunction of the endothelium. This layer of cells lines the inside of blood vessels and regulates many processes including new blood vessel formation, blood vessel diameter, blood clotting, the migration of circulating white blood cells, and the normal release of molecules involved in inflammation

"Because endothelial cells are so active, any perturbation in their function may have undesirable effects," explains Dr. Takashi Minami of the University of Tokyo. "Indeed, endothelial cell dysfunction underlies many disease states in humans, including--but certainly not limited to--stroke, coronary artery disease, cancer and preeclampsia. An important goal in vascular research is to develop new strategies that inhibit endothelial cell dysfunction and abnormal blood vessel formation."

Certain agonists, such as vascular endothelial growth factor and the serine protease thrombin, cause endothelial cells to increase their expression of genes involved in proliferation, inflammation, and thrombosis. Dr. Minami and his colleagues found that these agonists also turn on a gene that produces Down Syndrome Critical Region 1 (DSCR-1), and that DSCR-1 then negatively feeds back on the agonists and shuts off their production. Thus, DSCR-1 acts as a circuit breaker in agonist signaling, and serves in a negative feedback loop to inhibit endothelial cell activation and growth.

More
'"/>

Contact: Nicole Kresge
nkresge@asbmb.org
301-634-7415
American Society for Biochemistry and Molecular Biology
19-Nov-2004


Page: 1 2

Related biology news :

1. Discoverer of Sly Syndrome finds way of delivering medicine to fight rare genetic disorder
2. Researchers discover gene responsible for Restless Legs Syndrome
3. Study uncovers mutation responsible for Noonan Syndrome
4. New findings may lead to treatment for anxiety in Rett Syndrome
5. How Rett Syndrome mutation targets the brain
6. Brain derived neurotrophic factor alleviates disease symptoms in a mouse model of Rett Syndrome
7. Increasing norepinephrine stabilizes breathing patterns in a mouse model of Rett Syndrome
8. Univ. of Chicago scientists find potential cause of breathing problems in Rett Syndrome children
9. New data suggest pramipexole relieves symptoms of Restless Legs Syndrome (RLS) and is well-tolerated
10. Pramipexole delivered sustained efficacy in clinical trial of patients with Restless Legs Syndrome
11. Researchers at Yale identify a genetic link to Tourettes Syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017 Infectex Ltd., a Russian portfolio company ... clinical study of SQ109 added to the standard drug therapy regimen in patients with ... at Sequella, Inc. ( USA ) and the US National Institutes of ... ... Maxwell Biotech Venture Fund Logo ...
(Date:3/27/2017)... ... 2017 , ... PMG Research is pleased to announce its participation ... Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses on how ... and bring them closer to the patient. Clinical Trial Collaborations also will present an ...
(Date:3/27/2017)... , March 27, 2017 Neurotrope, ... novel therapies for neurodegenerative diseases, including Alzheimer,s disease, ... its application to list the Company,s common stock ... by The NASDAQ Stock Market, a unit of ... listing, Neurotrope will ring the Opening Bell at the ...
(Date:3/24/2017)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a ... today announced that its board of directors has amended its shareholder ... March 27, 2017 to March 27, 2018. The amendment was not in ... Ltd. ... Sinovac Biotech Ltd. is a China -based biopharmaceutical ...
Breaking Biology Technology:
Cached News: